Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) Director Acquires $151,800.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom bought 60,000 shares of the stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $2.53 per share, for a total transaction of $151,800.00. Following the acquisition, the director owned 147,555 shares of the company’s stock, valued at $373,314.15. This trade represents a 68.53% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Stock Up 2.9%

TLSI stock opened at $3.24 on Thursday. TriSalus Life Sciences, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The business’s 50-day moving average is $4.09 and its two-hundred day moving average is $5.09. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. The company has a market cap of $198.64 million, a price-to-earnings ratio of -2.30 and a beta of 0.56.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million. As a group, analysts forecast that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC bought a new stake in TriSalus Life Sciences during the 1st quarter valued at approximately $20,267,000. Nantahala Capital Management LLC grew its holdings in TriSalus Life Sciences by 1.5% during the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after buying an additional 30,582 shares in the last quarter. Wasatch Advisors LP bought a new stake in shares of TriSalus Life Sciences during the first quarter valued at approximately $5,752,000. Vanguard Group Inc. raised its position in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after buying an additional 345,186 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after buying an additional 265,618 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TLSI. Lake Street Capital decreased their price target on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings downgraded shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Canaccord Genuity Group decreased their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Finally, Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.